Amdinocillin pivoxil is under clinical development by UTILITY Therapeutics and currently in Pre-Registration for Urinary Tract Infections. According to GlobalData, Pre-Registration drugs for Urinary Tract Infections have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Amdinocillin pivoxil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Amdinocillin pivoxil overview

Amdinocillin pivoxil ((Selexid, X-systo, Xsysto) is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin. It is formulated as film coated tablets for oral route of administration. Selexid is indicated for the treatment of uncomplicated urinary tract infections caused by sensitive strains of E. coli, Klebsiella species, Enterobacteria species and Proteus species. Xsysto is indicated in adults for the treatment of acute uncomplicated cystitis caused by bacteria susceptible to mecillin

Amdinocillin pivoxil is under development for the treatment of complicated urinary tract infections (cUTI) and uncomplicated urinary tract infections (uUTIs). It is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin. It is administered by oral route. The drug candidate acts by targeting penicillin-binding protein 2 (PBP2).

UTILITY Therapeutics overview

UTILITY Therapeutics is a pharmaceutical company focused on the development and commercialization of antibiotics for the treatment of multi-drug resistant bacterial infections. Its offers products like mecillinam which is an antibacterial agent of beta-lactam antibiotic class and is used for the treatment of multiple serious infection diseases; and Pivmecillinam, an oral-prodrug of mecillinam used for the treatment of complicated urinary tract infections (cUTI). The company markets its products exclusively in the US and worldwide in IV oral formulation, and the oral formulation containing the pro-drug pivmecillinam HCl. UTILITY Therapeutics is headquartered in Cheshire, the UK.

For a complete picture of Amdinocillin pivoxil’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.